-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from the NEJM Journal Watch Review of Weight Loss with Adjustable Intragastric Balloon by Bruce Soloway, MD Most patients maintain a certain amount of weight for 6 months after device removal Decrease, but the long-term effect is unknown
.
Most behavioral and pharmacological treatments for obesity have limited efficacy and durability, and bariatric surgery, although effective and durable, is invasive and risky
.
A fluid-filled, intragastric balloon, used to occupy the stomach space, is placed in the stomach through an endoscope and left for 6 months
.
The device was associated with up to 10% weight loss, but was limited by patient intolerance and weight regain after device removal
.
In a manufacturer-funded study, researchers randomly assigned 288 obese adults (body mass index, 30 to 40 kg/m2) to life>
.
Investigators increased balloon volume at pre-specified intervals to enhance treatment efficacy, or decreased balloon volume to improve tolerance
.
Among the patients in the intragastric balloon group, 22% had the device removed prematurely due to intolerance
.
In the intention-to-treat analysis at 32 weeks, the mean weight loss in the intragastric balloon group was significantly greater than in the control group (15% vs.
3% of initial body weight); The intragastric balloon group significantly outperformed the control group (92% vs.
34%)
.
At 6 months after device removal, 74% of patients in the intragastric balloon group maintained more than 40% of their weight loss during treatment
.
Commentary Compared with bariatric surgery, adjustable intragastric balloons are minimally invasive, reversible, and do not alter anatomy
.
However, it requires repeated endoscopic adjustments, and the key question of long-term efficacy remains unanswered
.
The authors suggest that intragastric balloons may be useful in patients who require substantial weight loss in a short period of time, such as those preparing for surgery, even if weight loss is not maintained
.
Reviewed article Abu Dayyeh BK et al.
Adjustable intragastric balloon for treatment of obesity: A multicentre, open-label, randomised clinical trial.
Lancet 2021 Nov 27; 398:1965.
(https://doi.
org/10.
1016/S0140- 6736(21)02394-1) NEJM Journal Watch NEJM Journal Watch (NEJM Journal Watch) is published by the NEJM Group.
It invites internationally renowned doctors to comment on important papers in the medical field and helps doctors understand and apply the latest developments
.
"NEJM Frontiers of Medicine" translates several articles every week, publishes them on the app and official website, and selects 2-3 articles and publishes them on WeChat
.
Copyright Information This article was translated, written or commissioned by the NEJM Frontiers in Medicine, jointly created by Jiahui Medical Research and Education Group (J-Med) and The New England Journal of Medicine (NEJM)
.
The full text of the Chinese translation and the included figures are exclusively authorized by the NEJM Group
.
If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal responsibility
.
.
Most behavioral and pharmacological treatments for obesity have limited efficacy and durability, and bariatric surgery, although effective and durable, is invasive and risky
.
A fluid-filled, intragastric balloon, used to occupy the stomach space, is placed in the stomach through an endoscope and left for 6 months
.
The device was associated with up to 10% weight loss, but was limited by patient intolerance and weight regain after device removal
.
In a manufacturer-funded study, researchers randomly assigned 288 obese adults (body mass index, 30 to 40 kg/m2) to life>
.
Investigators increased balloon volume at pre-specified intervals to enhance treatment efficacy, or decreased balloon volume to improve tolerance
.
Among the patients in the intragastric balloon group, 22% had the device removed prematurely due to intolerance
.
In the intention-to-treat analysis at 32 weeks, the mean weight loss in the intragastric balloon group was significantly greater than in the control group (15% vs.
3% of initial body weight); The intragastric balloon group significantly outperformed the control group (92% vs.
34%)
.
At 6 months after device removal, 74% of patients in the intragastric balloon group maintained more than 40% of their weight loss during treatment
.
Commentary Compared with bariatric surgery, adjustable intragastric balloons are minimally invasive, reversible, and do not alter anatomy
.
However, it requires repeated endoscopic adjustments, and the key question of long-term efficacy remains unanswered
.
The authors suggest that intragastric balloons may be useful in patients who require substantial weight loss in a short period of time, such as those preparing for surgery, even if weight loss is not maintained
.
Reviewed article Abu Dayyeh BK et al.
Adjustable intragastric balloon for treatment of obesity: A multicentre, open-label, randomised clinical trial.
Lancet 2021 Nov 27; 398:1965.
(https://doi.
org/10.
1016/S0140- 6736(21)02394-1) NEJM Journal Watch NEJM Journal Watch (NEJM Journal Watch) is published by the NEJM Group.
It invites internationally renowned doctors to comment on important papers in the medical field and helps doctors understand and apply the latest developments
.
"NEJM Frontiers of Medicine" translates several articles every week, publishes them on the app and official website, and selects 2-3 articles and publishes them on WeChat
.
Copyright Information This article was translated, written or commissioned by the NEJM Frontiers in Medicine, jointly created by Jiahui Medical Research and Education Group (J-Med) and The New England Journal of Medicine (NEJM)
.
The full text of the Chinese translation and the included figures are exclusively authorized by the NEJM Group
.
If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal responsibility
.
